Page 84 - 南京医科大学自然版

第45卷第5期
·670 · 南 京 医 科 大 学 学 报 2025年5月

of the manuscript content and secured research funding. ［10］SANTORO M，ROMANO A，MANCUSO S，et al. Preven⁃
［参考文献］ tion of venous thromboembolic events occurring in myeloma
patients treated with second ⁃ generation novel agents［J］.
［1］ 陈丽萍，林 敏，霍春燕，等. 外周血 D⁃二聚体水平与
Panminerva Med，2021，63（1）：1-6
早期胃癌及癌前病变患者ESD术后下肢深静脉血栓的
［11］KAHALE L A，MATAR C F，TSOLAKIAN I，et al. Anti⁃
相关性研究［J］. 南京医科大学学报（自然科学版），
thrombotic therapy for ambulatory patients with multiple
2022，42（9）：1253-1258
myeloma receiving immunomodulatory agents［J］. Co⁃
CHEN L P，LIN M，HUO C Y，et al. Correlation between
chrane Database Syst Rev，2021，9（9）：CD014739
peripheral blood D⁃dimer level and deep venous thrombo⁃
［12］FUKATSU M，IKEZOE T. Cancer⁃associated thrombosis
sis after ESD in patients with early gastric cancer and pre⁃
in hematologic malignancies［J］. Int J Hematol，2024，119
cancerous lesions［J］. Journal of Nanjing Medical Univer⁃
（5）：516-525
sity（Natural Sciences），2022，42（9）：1253-1258 ［13］COSTA B A，COSTA T A，SARAVIA S D，et al. Thrombo⁃
［2］ YOKOYAMA K，MURATA M，IKEDA Y，et al. Incidence
embolic risk of carfilzomib or bortezomib in combination
and risk factors for developing venous thromboembolism
with lenalidomide and dexamethasone for newly diag⁃
in Japanese with diffuse large b ⁃ cell lymphoma［J］.
nosed multiple myeloma：a comparative systematic review
Thromb Res，2012，130（1）：7-11 and meta ⁃ analysis［J］. Am J Hematol，2024，99（6）：
［3］ KHORANA A A，MACKMAN N，FALANGA A，et al. 1056-1065
Cancer⁃associated venous thromboembolism［J］. Nat Rev ［14］ZONDER J A，CROWLEY J，HUSSEIN M A，et al. Le⁃
Dis Primers，2022，8（1）：11 nalidomide and high⁃dose dexamethasone compared with
［4］ KRISTINSSON S Y，PFEIFFER R M，BJÖRKHOLM M， dexamethasone as initial therapy for multiple myeloma：a
et al. Arterial and venous thrombosis in monoclonal gam⁃ randomized Southwest Oncology Group trial（S0232）［J］.
mopathy of undetermined significance and multiple my⁃ Blood，2010，116（26）：5838-5841
eloma：a population ⁃ based study［J］. Blood，2010，115 ［15］SCHOEN M W，CARSON K R，LUO S，et al. Venous
（24）：4991-4998 thromboembolism in multiple myeloma is associated with
［5］ KHADKA S，SOLANKI D，SINGH J，et al. Trends and out⁃ increased mortality［J］. Res Pract Thromb Haemost，
comes of venous thromboembolism in adult hospitaliza⁃ 2020，4（7）：1203-1210
tions with acute myeloid leukemia：analysis of nationwide ［16］LI X，SUN X，FANG B，et al. Development and validation
inpatient sample from 2010 to 2014［J］. Postgrad Med， of a new risk assessment modelfor immunomodulatory
2021，133（2）：160-165 drug ⁃ associated venous thrombosis among Chinese pa⁃
［6］ HERBRETEAU L，PAPAGEORGIOU L，LE CLECH L，et tients withmultiple myeloma［J］. Thromb J，2023，21（1）：
al. Benefice and pitfall of direct oral anticoagulants in 105
very high⁃risk myeloproliferative neoplasms［J］. Thromb ［17］HAN H J，KIM M，LEE J，et al. The risk of venous throm⁃
Res，2022，216：25-34 boembolism and ischemic stroke stratified by VTE risk
［7］ SANFILIPPO K M，LUO S，WANG T F，et al. Predicting following multiple myeloma：a Korean population ⁃ based
venous thromboembolism in multiple myeloma：develop⁃ cohort study［J］. J Clin Med. 2024，13（10）：2829
ment and validation of the IMPEDE VTE score［J］. Am J ［18］中华医学会血液学分会浆细胞疾病学组，中华医学会
Hematol，2019，94（11）：1176-1184 血液学分会血栓与止血学组. 多发性骨髓瘤相关静脉
［8］ LI A，WU Q，LUO S，et al. Derivation and validation of a 血栓栓塞症防治中国专家共识（2022年版）［J］. 中华血
risk assessment model for immunomodulatory drug⁃associ⁃ 液学杂志，2022，43（9）：726-731
ated thrombosis among patients with multiple myeloma［J］. Plasma Cell Diseases Group，Hematology Society，Chi⁃
J Natl Compr Canc Netw，2019，17（7）：840-847 nese Medical Association. Consensus of China experts on
［9］ BARBAR S，NOVENTA F，ROSSETTO V，et al. A risk as⁃ prevention and treatment of multiple myeloma associated
sessment model for the identification of hospitalized medi⁃ venous thromboembolism（2022 edition）［J］. Chinese
cal patients at risk for venous thromboembolism：the Pad⁃ Journal of Hematology，2022，43（9）：726-731
ua prediction score［J］. J ThrombHaemost，2010，8（11）： ［收稿日期］ 2024-10-29
2450-2457 （本文编辑：唐 震）